ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- ESR Essentials: imaging of melanoma-practice recommendations by the European Society of Oncologic Imaging.European radiology · 2026Guideline
- Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics.ACS pharmacology & translational science · 2026Review
- Radiopharmaceuticals in Malignant Melanoma: A Comprehensive Review of Diagnostic, Therapeutic, and Immune-Related Applications by PET/CT, SPECT/CT, and PET/MRI.Diagnostics (Basel, Switzerland) · 2025Review
- Development ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological Heterogeneity.Molecular imaging and biology · 2025Article
- Head-to-head evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Novel Clinical PET Tracers in the Pipeline for Melanoma.Current oncology reports · 2025Review
- First-in-human PET imaging and evaluation of melanin-targeted [Theranostics · 2025Article
- A Novel Melanin-TargetedKorean journal of radiology · 2024Article
- Melanin-targeted [European journal of nuclear medicine and molecular imaging · 2023Article
- Prospective comparison of [EJNMMI research · 2023Article
- MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.Acta pharmacologica Sinica · 2022Review
- PET imaging to assess fibroblast activation protein inhibitor biodistribution: A training program adapted to pharmacology education.Pharmacology research & perspectives · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.